AIDS Vaccine Advocacy Coalition Survey, Annual Report, Call for Increased Public Funding of AIDS Vaccine Research
Private firms are "stepping up" efforts to develop an AIDS vaccine, but more government support is needed to "maintain the momentum," according to a survey released yesterday by the AIDS Vaccine Advocacy Coalition as part of its annual report on the status of AIDS vaccine research. The survey examined the efforts of 11 pharmaceutical and biotechnology companies working on AIDS vaccine research. AVAC found that more public-sector funding is needed to expand product development and manufacturing, increase the number of international sites where AIDS vaccine trials can be conducted and ensure the purchase of AIDS vaccines for "rapid global delivery." The AVAC report, titled, "How Do You Fight a Disease of Mass Destruction?," suggests an increase in NIH and FDA funding, a boost in assistance to product developers and expanded clinical trial capacity internationally, according to an AVAC release. AVAC Executive Director Chris Collins said, "When America became frightened by the bioterror threat, Congress and the Administration moved swiftly to put funding and incentives in place. That same kind of decisive action is needed to accelerate research and ensure an AIDS vaccine is available to all who need it" (AVAC release, 5/15).This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.